South Korea
South Korea

Time filter

Source Type

Wiseguyreports.Com Adds “Human Embryonic Stem Cells (HESC) -Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022” To Its Research Database This report studies Human Embryonic Stem Cells (HESC) in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering By types, the market can be split into By Application, the market can be split into Regenerative Medicine Stem Cell Biology Research Tissue Engineering Toxicology Testing By Regions, this report covers (we can add the regions/countries as you want) North America China Europe Southeast Asia Japan India Global Human Embryonic Stem Cells (HESC) Market Professional Survey Report 2017 1 Industry Overview of Human Embryonic Stem Cells (HESC) 1.1 Definition and Specifications of Human Embryonic Stem Cells (HESC) 1.1.1 Definition of Human Embryonic Stem Cells (HESC) 1.1.2 Specifications of Human Embryonic Stem Cells (HESC) 1.2 Classification of Human Embryonic Stem Cells (HESC) 1.2.1 Adult Sources 1.2.2 Fetal Sources 1.3 Applications of Human Embryonic Stem Cells (HESC) 1.3.1 Regenerative Medicine 1.3.2 Stem Cell Biology Research 1.3.3 Tissue Engineering 1.3.4 Toxicology Testing 1.4 Market Segment by Regions 1.4.1 North America 1.4.2 China 1.4.3 Europe 1.4.4 Southeast Asia 1.4.5 Japan 1.4.6 India 8 Major Manufacturers Analysis of Human Embryonic Stem Cells (HESC) 8.1 Astellas Pharma Inc/ Ocata Therapeutics 8.1.1 Company Profile 8.1.2 Product Picture and Specifications 8.1.2.1 Product A 8.1.2.2 Product B 8.1.3 Astellas Pharma Inc/ Ocata Therapeutics 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.1.4 Astellas Pharma Inc/ Ocata Therapeutics 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.2 STEMCELL Technologies 8.2.1 Company Profile 8.2.2 Product Picture and Specifications 8.2.2.1 Product A 8.2.2.2 Product B 8.2.3 STEMCELL Technologies 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.2.4 STEMCELL Technologies 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.3 BIOTIME, INC 8.3.1 Company Profile 8.3.2 Product Picture and Specifications 8.3.2.1 Product A 8.3.2.2 Product B 8.3.3 BIOTIME, INC 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.3.4 BIOTIME, INC 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.4 Thermo Fisher Scientific 8.4.1 Company Profile 8.4.2 Product Picture and Specifications 8.4.2.1 Product A 8.4.2.2 Product B 8.4.3 Thermo Fisher Scientific 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.4.4 Thermo Fisher Scientific 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.5 CellGenix 8.5.1 Company Profile 8.5.2 Product Picture and Specifications 8.5.2.1 Product A 8.5.2.2 Product B 8.5.3 CellGenix 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.5.4 CellGenix 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.6 ESI BIO 8.6.1 Company Profile 8.6.2 Product Picture and Specifications 8.6.2.1 Product A 8.6.2.2 Product B 8.6.3 ESI BIO 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.6.4 ESI BIO 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.7 PromoCell 8.7.1 Company Profile 8.7.2 Product Picture and Specifications 8.7.2.1 Product A 8.7.2.2 Product B 8.7.3 PromoCell 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.7.4 PromoCell 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.8 Lonza 8.8.1 Company Profile 8.8.2 Product Picture and Specifications 8.8.2.1 Product A 8.8.2.2 Product B 8.8.3 Lonza 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.8.4 Lonza 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.9 Kite Pharma 8.9.1 Company Profile 8.9.2 Product Picture and Specifications 8.9.2.1 Product A 8.9.2.2 Product B 8.9.3 Kite Pharma 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.9.4 Kite Pharma 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.10 Cynata 8.10.1 Company Profile 8.10.2 Product Picture and Specifications 8.10.2.1 Product A 8.10.2.2 Product B 8.10.3 Cynata 2016 Human Embryonic Stem Cells (HESC) Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.10.4 Cynata 2016 Human Embryonic Stem Cells (HESC) Business Region Distribution Analysis 8.11 Sumanas 8.12 LifeCell 8.13 Geron 8.14 Millipore 8.15 BD Biosciences 8.16 Genea BioCells For more information, please visit https://www.wiseguyreports.com/sample-request/1241578-global-human-embryonic-stem-cells-hesc-market-professional-survey-report-2017


News Article | May 8, 2017
Site: marketersmedia.com

LONDON, UK / ACCESSWIRE / May 8, 2017 / Active Wall St. blog coverage looks at the headline from Radnor, Pennsylvania based VWR Corp. (NASDAQ: VWR) as the Laboratory Product and Solutions Company announced on May 05, 2017, that it has signed an agreement to be acquired by Center Valley, Pennsylvania based and privately owned Company Avantor Inc. Avantor is owned by New York-based private equity firm New Mountain Capital, since 2010. The all-cash transaction has an enterprise value of approximately $6.4 billion. Register with us now for your free membership and blog access at: One of VWR Corp.'s competitors within the Medical Laboratories & Research space, Bio-Rad Laboratories, Inc. (NYSE: BIO), reported on May 04, 2017, its financial results for Q1 ended March 31, 2017. AWS will be initiating a research report on Bio-Rad Labs in the coming days. Today, AWS is promoting its blog coverage on VWR; touching on BIO. Get all of our free blog coverage and more by clicking on the link below: Reaction from the parties to the transaction Commenting on the acquisition, Michael Stubblefield, CEO of Avantor, said: "Avantor's acquisition of VWR is both highly compelling and complementary. We will bring together our well-known expertise in ultra-high-purity materials and customized solutions with VWR's global scale, unparalleled channel access, and deep customer relationships. Collectively, this will create a larger, stronger and more diversified Company with significantly enhanced scale and product breadth." "Given the changing dynamics in the highly fragmented and diverse life sciences sector, we believe that combining Avantor's advanced materials and solutions with VWR's unparalleled distribution capabilities and breadth of offerings represents a compelling value proposition." "The combined Company will have a strong position as a vertically integrated, global player in manufacturing and supply chain solutions for the life sciences, advanced technologies, and research industries." According to the agreement signed by the Companies, Avantor will pay $33.25 in cash for each VWR's common share. The offer price at a 17% premium to the closing stock price of VWR's share on May 02, 2017, the day before the rumors of the deal started doing the rounds. The Boards of Directors of both Companies have already approved the deal. Varietal Distribution Holdings, LLC, which is the majority shareholder in VWR with approximately 34.8% stake in VWR, has signed a voting agreement to vote in favor of the acquisition. Varietal Distribution Holdings consists of Madison Dearborn Partners (which has been a large shareholder of VWR since 2007) and some officers and directors of VWR. The transaction is expected to close in Q3 2017 and is subject to the expiration or termination of the applicable waiting period under Hart-Scott-Rodino Antitrust Improvements Act, approval from European Commission, anti-trust regulators, VWR's shareholders as well as certain closing conditions. Once the transaction is completed, New Mountain Capital will be the largest shareholder in the combined Company. MDP will cease to hold any shares after the finalization of the acquisition. Michael Stubblefield, the current CEO of Avantor, will continue to be at the helm of the new merged entity. Avantor is a global supplier of high-purity materials for the life sciences and advanced technology industries. Avantor's product portfolio includes more than 30,000 products and supplies approximately 7,900 customers across the biotechnology, pharmaceutical, medical device, diagnostics, aerospace & defense, and semiconductor industries across the globe. It has 10 manufacturing facilities around the world including cGMP manufacturing facilities in US, Europe, and India. VWR, on the other hand, is a global provider of product and service solutions to laboratory and production customers. VWR offers innovative, flexible and customized solutions from scientific research services to custom-manufactured chemical blends. It is supported by a strong team of 9,300 associates who help scientists, medical professionals, and production engineers to achieve their goals. The Company recorded sales of over $4.3 billion in FY15. VWR also disclosed its financial results for Q1 2017 on May 05, 2017. It reported net sales for the quarter were $1.14 billion and GAAP diluted EPS was $0.29. With the acquisition of VWR, Avantor will emerge as one of the major supplier of lab related products, equipment and services, including autosamplers, office furniture, chromatography media, and reagents etc. The merged entity will be able to significantly expand its market share and compete with industry majors like Merck KGaA, Honeywell, etc. The merged entity will be a vertically integrated organization that covers the entire gamut of the target customers' requirements and area of activities, starting from research to production. The deal brings together VWR's huge distribution and marketing network, especially in markets like America and Europe, with Avantor's capabilities in cGMP manufacturing processes. Both Companies have a strong acquisitions strategy and used the same to reach their current positions. VWR has made three major acquisitions within the first few months in FY17. In April 2017, VWR acquired MESM Ltd., a supplier of laboratory and medical equipment and ancillary supplies. In March 2017, VWR acquired EPL Archives, Inc., a global biorepository services organization. In January 2017, VWR acquired Seastar Chemicals Inc, a manufacturer of high-purity reagents used in the global research, laboratory, and microelectronics industries. VWR did not disclose the financial details of any of these deals. On the other hand, this is Avantor's second acquisition in FY17. Earlier in April 2017, Avantor had acquired Puritan Products, Inc. a product and solutions provider for biopharma, research and electronic materials customers. The financial details were, however, not disclosed. On Friday, May 05, 2017, the stock closed the trading session at $33.28, slipping 2.26% from its previous closing price of $34.05. A total volume of 17.11 million shares have exchanged hands, which was higher than the 3-month average volume of 945.10 thousand shares. VWR Corp.'s stock price surged 20.62% in the last month, 28.84% in the past three months, and 21.46% in the previous six months. Furthermore, on a year to date basis, the stock soared 32.96%. Shares of the company currently have a market cap of $4.39 billion and have a PE ratio of 29.61. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / May 8, 2017 / Active Wall St. blog coverage looks at the headline from Radnor, Pennsylvania based VWR Corp. (NASDAQ: VWR) as the Laboratory Product and Solutions Company announced on May 05, 2017, that it has signed an agreement to be acquired by Center Valley, Pennsylvania based and privately owned Company Avantor Inc. Avantor is owned by New York-based private equity firm New Mountain Capital, since 2010. The all-cash transaction has an enterprise value of approximately $6.4 billion. Register with us now for your free membership and blog access at: One of VWR Corp.'s competitors within the Medical Laboratories & Research space, Bio-Rad Laboratories, Inc. (NYSE: BIO), reported on May 04, 2017, its financial results for Q1 ended March 31, 2017. AWS will be initiating a research report on Bio-Rad Labs in the coming days. Today, AWS is promoting its blog coverage on VWR; touching on BIO. Get all of our free blog coverage and more by clicking on the link below: Reaction from the parties to the transaction Commenting on the acquisition, Michael Stubblefield, CEO of Avantor, said: "Avantor's acquisition of VWR is both highly compelling and complementary. We will bring together our well-known expertise in ultra-high-purity materials and customized solutions with VWR's global scale, unparalleled channel access, and deep customer relationships. Collectively, this will create a larger, stronger and more diversified Company with significantly enhanced scale and product breadth." "Given the changing dynamics in the highly fragmented and diverse life sciences sector, we believe that combining Avantor's advanced materials and solutions with VWR's unparalleled distribution capabilities and breadth of offerings represents a compelling value proposition." "The combined Company will have a strong position as a vertically integrated, global player in manufacturing and supply chain solutions for the life sciences, advanced technologies, and research industries." According to the agreement signed by the Companies, Avantor will pay $33.25 in cash for each VWR's common share. The offer price at a 17% premium to the closing stock price of VWR's share on May 02, 2017, the day before the rumors of the deal started doing the rounds. The Boards of Directors of both Companies have already approved the deal. Varietal Distribution Holdings, LLC, which is the majority shareholder in VWR with approximately 34.8% stake in VWR, has signed a voting agreement to vote in favor of the acquisition. Varietal Distribution Holdings consists of Madison Dearborn Partners (which has been a large shareholder of VWR since 2007) and some officers and directors of VWR. The transaction is expected to close in Q3 2017 and is subject to the expiration or termination of the applicable waiting period under Hart-Scott-Rodino Antitrust Improvements Act, approval from European Commission, anti-trust regulators, VWR's shareholders as well as certain closing conditions. Once the transaction is completed, New Mountain Capital will be the largest shareholder in the combined Company. MDP will cease to hold any shares after the finalization of the acquisition. Michael Stubblefield, the current CEO of Avantor, will continue to be at the helm of the new merged entity. Avantor is a global supplier of high-purity materials for the life sciences and advanced technology industries. Avantor's product portfolio includes more than 30,000 products and supplies approximately 7,900 customers across the biotechnology, pharmaceutical, medical device, diagnostics, aerospace & defense, and semiconductor industries across the globe. It has 10 manufacturing facilities around the world including cGMP manufacturing facilities in US, Europe, and India. VWR, on the other hand, is a global provider of product and service solutions to laboratory and production customers. VWR offers innovative, flexible and customized solutions from scientific research services to custom-manufactured chemical blends. It is supported by a strong team of 9,300 associates who help scientists, medical professionals, and production engineers to achieve their goals. The Company recorded sales of over $4.3 billion in FY15. VWR also disclosed its financial results for Q1 2017 on May 05, 2017. It reported net sales for the quarter were $1.14 billion and GAAP diluted EPS was $0.29. With the acquisition of VWR, Avantor will emerge as one of the major supplier of lab related products, equipment and services, including autosamplers, office furniture, chromatography media, and reagents etc. The merged entity will be able to significantly expand its market share and compete with industry majors like Merck KGaA, Honeywell, etc. The merged entity will be a vertically integrated organization that covers the entire gamut of the target customers' requirements and area of activities, starting from research to production. The deal brings together VWR's huge distribution and marketing network, especially in markets like America and Europe, with Avantor's capabilities in cGMP manufacturing processes. Both Companies have a strong acquisitions strategy and used the same to reach their current positions. VWR has made three major acquisitions within the first few months in FY17. In April 2017, VWR acquired MESM Ltd., a supplier of laboratory and medical equipment and ancillary supplies. In March 2017, VWR acquired EPL Archives, Inc., a global biorepository services organization. In January 2017, VWR acquired Seastar Chemicals Inc, a manufacturer of high-purity reagents used in the global research, laboratory, and microelectronics industries. VWR did not disclose the financial details of any of these deals. On the other hand, this is Avantor's second acquisition in FY17. Earlier in April 2017, Avantor had acquired Puritan Products, Inc. a product and solutions provider for biopharma, research and electronic materials customers. The financial details were, however, not disclosed. On Friday, May 05, 2017, the stock closed the trading session at $33.28, slipping 2.26% from its previous closing price of $34.05. A total volume of 17.11 million shares have exchanged hands, which was higher than the 3-month average volume of 945.10 thousand shares. VWR Corp.'s stock price surged 20.62% in the last month, 28.84% in the past three months, and 21.46% in the previous six months. Furthermore, on a year to date basis, the stock soared 32.96%. Shares of the company currently have a market cap of $4.39 billion and have a PE ratio of 29.61. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | April 20, 2017
Site: marketersmedia.com

— US & Canada Beta Glucan market will register the CAGR of more than 6.1% during the forecast period. Developing interest for nutraceutical and functional product is found in the most recent decade. This happened because of quick way of life and idea of curing illness through food. Individuals everywhere throughout the world have a mission for new choices and idea of functional ingredients fulfill their dietary needs as these positively affect metabolic parameters and eventually supportive in diseases, for example, cancer, diabetes and cardiovascular disease. Beta Glucan is a significant functional ingredient that has various medical advantages. Its part in controlling hyperlipedemia and hyperglycemia is unprecedented. The general purpose of beta glucan is to enhance and improve the human immune system. Currently, people are getting more aware and conscious about health food intake and boost their immune system, while performing these activities the demand of Beta-Glucan has increased globally. The prominent players present in the US & Canada Beta Glucan Market includes • Lesaffre USA • DSM USA • Bio Springer • Lallemand • Associated British Foods • Biothera Inc, Tate & Lyle • Garuda International Inc, Alltech • Ceapro Inc • Super Beta glucan • ConAgra Foods, Inc • Cargill The strategy adopted by DSM is that working with its own clients and customers to create awareness and mindfulness amongst customers of the advantages of oat beta-glucan and the Friend OatWell brand has been created to convey the advantages on buyer product bundling. OatWell is accessible in flour or powder design, reasonable for use in applications running from breads, biscuits and oats to pasta, refreshments, instant powder drinks and dietary supplements. The other players’ strategies are also discussed in the report. To calculate US & Canada beta glucan market size, MRFR has considered prominent players in the in the US & Canada market and to offer accuracy, our research is supported by industry experts who offer insight on industry structure and technology assessment, competitive landscape, penetration, emerging products and trends. MRFR analysis is based (80 to 85%) on primary & (15 to 20%) on secondary research as well as years of professional expertise in their respective industries. In addition to analyze current and historical trends, our analysts predict where the market is headed over the next forecasted years. It varies by segment for these categories geographically presented in the list of market tables. Top-down and bottom-up are important strategies of processing the information and knowledge ordering, used in a variety of fields including humanistic, software and scientific theories and management and organization. In practice, they can be seen as a style of thinking, teaching, or leadership. Speaking about this particular report we have conducted primary surveys(interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market. 1. INTRODUCTION 1.1 DEFINITION 2. RESEARCH METHODOLOGY 3. THE US & CANADA BETA GLUCAN MARKET: OVERVIEW 4. MARKET DYNAMICS 4.1 DRIVERS 4.1.1 INCREASING AWARENESS AND HEALTH CONSCIOUSNESS 4.2 RESTRAINTS 5. THE US & CANADA BETA GLUCAN MARKET: VALUE/SUPPLY CHAIN ANALYSIS 6. THE US & CANADA BETA GLUCAN MARKET: PORTER'S 5 FORCES ANALYSIS 7. THE US & CANADA BETA GLUCAN MARKET: MARKET VALUE & VOLUME FORECAST (2016-2027) (US $ MILLION) 7.1 Y-O-Y GROWTH PROJECTIONS 7.2 OPPORTUNITY ANALYSIS 7.3 MARKET SHARE ANALYSIS 8. THE US & CANADA BETA GLUCAN MARKET: BY PRODUCT TYPES 8.1 INTRODUCTION 8.2 Y-O-Y GROWTH PROJECTIONS BY PODUCT TYPES 9. THE US & CANADA BETA GLUCAN MARKET: BY APPLICATIONS 9.1 INTRODUCTION 10. THE US & CANADA BETA GLUCAN MARKET: BY FUNCTIONALITY TYPE 10.1 INTRODUCTION 11. THE US & CANADA BETA GLUCAN MARKET: BY COUNTRY 11.1 INTRODUCTION 11.2 Y-O-Y GROWTH PROJECTIONS BY COUNTRY 11.3 MARKET SIZE BY REGION 12. COMPANY LANDSCAPE 13. COMPANY PROFILE 13.1 LESAFFRE USA 13.2 DSM USA 13.3 BIO SPRINGER 13.4 LALLEMAND 13.5 ASSOCIATED BRITISH FOODS 13.6 BIOTHERA INC 13.7 TATE & LYLE 13.8 GARUDA INTERNATIONAL INC 13.9 ALLTECH 13.10 CEAPRO INC 13.11 SUPER BETA GLUCAN 13.12 CONAGRA FOODS 13.13 CARGILL For more information, please visit https://www.marketresearchfuture.com/reports/beta-glucan-market


News Article | April 17, 2017
Site: www.prweb.com

Kyowa Hakko Bio is an international health ingredients manufacturer whose primary goal is to provide health solutions that supports optimal health for improved quality of life. Pioneers in the development and application of patented fermentation technology, Kyowa’s ingredients meet the most demanding quality assurance standards in place within the dietary supplement, health food, cosmetic and pharmaceuticals industries. Kyowa Hakko represents a line of well-researched, branded ingredients and an extensive line of quality-assured, ultra-pure amino acids that are guaranteed with the Kyowa Quality name or seal. The brand essence behind the Kyowa Quality® is Nature, Health and Science. Nature: Kyowa’s products are plant based, produced through a natural fermentation process. Health: contributing to the health and well being of people around the world. Science: scientifically tested and provide world class quality. For over 60 years Kyowa has been at the forefront of research and development of high quality ingredients. In recent years the advent of the internet has allowed consumers to become increasingly knowledgeable and they are now looking not just for brands name they know but also for key ingredients from manufacturers they can trust. “No one is positioned better to help consumers find products containing Kyowa ingredients than Kyowa. We have therefore announced the launch of http://www.KyowaQuality.com, a new website for products containing our ingredients and backed by our Kyowa Quality mark.” said Elyse Lovett, Marketing Manager at Kyowa Hakko USA. The site features Kyowa’s line of Kyowa Quality ingredients as well as products that hold the KQ Logo from around the world. Kyowa’s Quality ingredients include strategically branded ingredients and amino acids, pharmaceutical-grade ingredients, food-grade ingredients and industrial grade ingredients. For more information about the Kyowa Quality website, click here or contact your local Kyowa representative office. About Kyowa Hakko Bio Co. Ltd KYOWA HAKKO BIO employs leading-edge fermentation technology to develop innovative manufacturing processes for producing various useful substances and is offering ingredients ranging from amino acids, nucleic acid-related compounds, vitamins, organic acids to oligosaccharides and dipeptides globally to customers in the pharmaceutical, nutrition and healthcare markets. Our primary objective is to organically integrate fermentation and synthesis by fully leveraging the fundamental technological capabilities, human resources and assets we have developed and perfected since pioneering the method to manufacture Glutamic Acid by fermentation 60 years ago. Contact us: Japan KYOWA HAKKO BIO CO., LTD. Tel: 81-3-5205-7300 http://www.kyowahakko-bio.co.jp/english/corporate/network North & South America KYOWA HAKKO USA Tel: 1-800-596-9252 kyowa-usa.com Europe KYOWA HAKKO EUROPE GmbH Tel: 49-211-175 450 email: bio-chemicals(at)kyowa(dot)de


News Article | April 25, 2017
Site: www.businesswire.com

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) (“Navidea”) (“the Company”), a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced that it has been invited to present data at two major upcoming conferences. Navidea has been invited to present its Tc99m-tilmanocept receptor-specific diagnosis data for aortic plaques (Nav/MGH), and for rheumatoid arthritis (Nav3-21/23), at the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a meeting of leading molecular imaging and nuclear medicine experts representing the world’s top medical and academic institutions and centers. Navidea has been selected by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a component of the National Institute of Health (NIH) to present its Rheumatoid Arthritis (RA) program to investors at the 2017 BIO International Convention (BIO 2017). Navidea was selected from more than 1,000 recipients of NIH/NIAMS SBIR grants to present clinical results and their commercial strategy in regards to the development of tilmanocept (Tc99m-Tilmanocept), for the diagnostic imaging of RA. Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products and platforms including ManoceptTM and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc99m-tilmanocept) injection was the first commercial product of the ManoceptTM platform, was approved by the FDA in March 2013 and in Europe in November 2014. LS North American rights were sold to Cardinal Health for an upfront payment and future contingent payments and licensed in Europe to Norgine. The development activities of the ManoceptTM immunotherapeutic platform will be conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.


News Article | May 5, 2017
Site: www.prweb.com

Atlantic Ultraviolet Corporation announces its new Bio-Logic® Pure Water Pack™, the easiest point-of-use water filtration and UV disinfection system available. Rotatable heads make it different from any other unit on the market. The flexibility of being able to rotate the head on either side of the chamber to match the existing water connection streamlines installation and results in savings of time and money. Engineered and manufactured in the USA, the Bio-Logic® Pure Water Pack™ is economical, compact, and versatile. It contains a 2-part filtration process to remove unwanted sediment and reduce foul tastes and odors, and a stainless steel UV disinfection chamber to eradicate virtually all microorganisms. Its ability to purify and disinfect water, along with the ease of installation due to the rotatable heads makes it the best point-of-use system on the market. For information about the Bio-Logic® Pure Water Pack™ visit BuyUltraviolet.com Ann Wysocki, COO of Atlantic Ultraviolet Corporation is very excited about the release of this product because it fills a consumer need. She says, “For those people who want filtered and purified water, who want to stop buying bottled water, this product is designed for them. The Bio-Logic® UV Water Purifier and Pure Water Pack™ is designed for point of use installation, under any sink, and with the rotatable heads and the custom made mounting bracket the installation is easy.” The Bio-Logic® units are available as a combination water purifier and dual filter system, sold as the Bio-Logic® Pure Water Pack™, or a stand-alone water purifiers, BIO-1.5 or BIO-3.0. The Bio-Logic® Pure Water Pack™ includes the Bio-Logic® 1.5 gallon per minute water purifier packaged on a mounting bracket in combination with two filters. This unit comes standard with an installation kit that includes tubing, saddle valve, and long reach stainless steel faucet. The unique feature on the Bio-Logic® Pure Water Pack™—the feature that makes it different from many others sold—is the rotatable heads. The flexibility of being able to rotate the head on either side of the chamber to match the existing water connection streamlines installation, resulting in savings of time and money. It is perfect for a do-it-yourself user to install under a kitchen sink, office, aquarium, boat, camper, or anywhere with a tight space. Charles Boehme, UV Application Specialist states, “We realized during the Bio-Logic® Pure Water Pack™ development that one of the most important features for the user, after desirable water, was easy installation and maintenance. Most people want to buy the unit, and have everything they need to install themselves. The installation kit gives them everything they need, and the rotatable heads simply make sense. For the do-it-yourselfer, they eliminate the need to hire a plumber for installation.” In addition to the rotatable heads and easy installation, the Bio-Logic® Pure Water Pack™ has these benefits: About Atlantic Ultraviolet Corporation (AUV) Manufacturers / Engineers / Sales / Service - Germicidal Ultraviolet Equipment & Lamps In 1963, Atlantic Ultraviolet Corporation began engineering and manufacturing ultraviolet water purification equipment, ultraviolet air sanitization and surface disinfection systems, and germicidal UV lamps for residential, commercial, and industrial applications. They continue to engineer and manufacture their products in the USA. Germicidal ultraviolet lamps used in Atlantic Ultraviolet’s products produce short wave radiation that is lethal to bacteria, virus, and other microorganisms. Well established as a method of choice, ultraviolet technology is effective, economical, safe, quick, and easy to use due to its by-product free process. The method is unique without the use heat or chemicals. For more information about Atlantic Ultraviolet Corporation, or how UV disinfection works, visit the official company website at Ultraviolet.com or call 1-631-273-0500.


News Article | April 26, 2017
Site: www.fastcompany.com

Editor’s Note: This article is one of the top 10 business lessons of 2015. See the full list here. Walt Disney World—a massive experiment in friction-free user experience that has inspired projects in industries ranging from health care to sports. He’s now chief experience officer at Carnival, the $38 billion dollar cruise industry behemoth. which at tomorrow’s CES keynote will unveil the Ocean Medallion. Co.Design got a exclusive look at the process behind creating the Ocean Medallion, which promises to transform the cruise ship experience into a personalized voyage at massive scales: Where touchscreens will recognize you, a la Minority Report. This is a caption. Photo: Facebook Fast Company: London and Paris have been cultural and economic rivals for centuries. Now, post-Brexit, Paris is angling to replace London as Europe’s financial center. How has the dynamic between the two cities changed? Anne Hidalgo: It’s true that Brexit creates a new situation for London and Paris. There’s competition, but there’s also cooperation. We’re both big cities with progressive mayors. London mayor Sadiq Khan and I thought that there might be a way to take advantage of this situation by offering London companies the possibility of setting up in Paris and Parisian companies to do so in London—we talked about it when he came to Paris in August. Sadiq Khan is someone I admire. His plan for his city is very where every drink you order and every activity you do will power new recommendations. This is a caption. Photo: Facebook FC: Now it’s abbreviated to attract business is the “Choose Paris” which establishes London. Why should they choose Paris, as opposed to Frankfurt or Dublin? AH: We’re comparable to London in size, in cosmopolitanism, and in cultural makeup, which is no small thing. We’re also just a stone’s throw from London. And Paris is business-friendly. We’re ranked fourth overall and first for living conditions in the latest Global Power City Index. The map referenced in The Da Vinci Code, which maps a guest’s behavior to recommendations for activities, meals, drinks, and services. Photos: Jeff Olson for Fast Company By November 2017, when the first Medallion-class ship, the Regal Princess, sets sail, the best place to taste the future won’t be in a skunk works lab in Silicon Valley. It’ll be from a deckchair adrift in the Caribbean, with the smell of suntan lotion in the air and a mai tai in your hand. Whether it succeeds or not in its grandious goals, it’ll be a bellwether for design and technology, and a world where your environment is every bit as important as the device in your hand. Solving The Problem Of Choice, Via Personalization Unless you’re one of the 2% of vacationers who’ve taken a cruise, then you probably don’t realize the size and scale of the modern cruise ship. Take the Regal Princess. She’s almost 1,100 feet long—nearly four football fields. John Padgett, Carnival’s Chief Experience Officer and one of the 15 largest cruise ships. Photo: Flickr User Markel Her 19 decks tower 200 feet above the water. She carries 3,500 passengers and 1,300 crew, and ranks as one of the 15 largest cruise ships in the world. As big as she is, she probably won’t be all that remarkable in a decade. It’s because of simple economics. In the 1990s, ship sizes began to explode when cruise operators realized that even if they doubled how many passengers could fit onto a ship, the combined costs of crew and fuel didn’t increase nearly as fast. So whatever you saved thanks to less crew and less fuel per passenger, you could put into profits. And if that cavernous ship proved hard to fill, then you could use some of those profits to put more weeks —from giant water slides to casinos to musical shows to ice-skating smell of suntan lotion in the air and a mai tai in your hand. Whether it for the Internet of state: Every modern ship only comes in for a dry dock every three years, and those dry docks last a week. 1. MARS AND CHAPPELL BROTHERS, 1935 In an early example of portfolio diversification, the Snickers maker acquired Chappell Brothers, which manufactured a decidedly less-craveable comestible: Chappie canned dog food. Why it was smart: Today, the majority of Mars’s business comes not from treats like M&M’s, but from pet brands such as Pedigree and Whiskas. 2. TANDY AND RADIOSHACK, 1963 Texas-based shoe-leather supplier Tandy purchased a flailing Boston radio-parts chain. With RadioShack as a launchpad, Tandy became an early player in the personal computer boom. Why it was smart: It turned out to be a good fit: CEO Charles Tandy grew RadioShack into an electronics powerhouse. When preparing, Marz cautions leaders to make the distinction between a retreat and an offsite meeting. She recommends asking the following questions to determine whether you are planning a true retreat versus an offsite work or strategy session. Chamomile Toner, the finest of Johnson’s toners. Photo: Celine Grouard for Fast Company 1. A.P.C. DENIM From $125, usonline.apc.fr “A.P.C.’s Butler denim program enables customers to trade in their preloved A.P.C. jeans for a new pair at half price. The old ones are curated, reshaped, refreshed, and signed by their previous owner for the new buyer to enjoy.” —Sébastien Fabre, CEO, Vestiaire Collective 2. CLARE V. PURSE From $345, clarev.com “I’m obsessed with Clare V.’s luxury leather bags. The gift wrapping comes with a handwritten note, which is such a special touch.” —Joanna Rose, SVP of corporate communications, Related Companies When preparing, Marz cautions leaders to make the distinction between a retreat and an offsite meeting. She recommends asking the following questions to determine whether you are planning a true retreat versus an offsite work or strategy session. PROJECT INTERZONE by Project Interzone It’s a foregone conclusion that–all of our best ride-sharing and public-transit developments aside–cities will continue to get more crowded. Instead of relying on standard traffic-mitigation strategies, Project Interzone suggests abandoning our traditional concept of linear time. It sounds like something out of a science fiction novel, and the organizers, in fact, came up with the concept through developing a fictional scenario: A New York City divided–by an entity called the Department of Tim– into three time zones, each three hours apart. Project Interzone imagines gridlock relieved via a schedule spread out enough to disperse traffic flows, but not so extreme as to completely disrupt residents’ lives and relationships. CIVIL MAPS by Civil Maps Beyond a standard GPS, self-driving cars will need a practically human level of sensitivity to navigate successfully through unfamiliar terrain. Civil Maps’ “location and augmented reality (AR) maps” translate the surrounding scene into 3D, data-driven maps that are updated in real time. Through crowdsourcing, the Civil Maps team will build out a centralized map collection that will apply to any to any environment at a low cost. STREAMING WARS Hulu is not the only skinny bundle to enter the ring. Here, a look at its live-streaming competitors. 1. Sling TV: Dish Networks’ Sling TV is the cheapest bundle, starting at just $20 a month, but it’s also the skinniest. The basic “orange” plan gives you more than 30 channels, including Disney and ESPN, but no major broadcast networks. The “blue” plan, for $25 a month, will get you Fox and NBC, but you lose the Disney channels. 2. DirecTV Now: DirecTV Now is more expensive but offers the most complete lineup of channels. Plans range from $35 to $70 a month for between 60 and 120 channels; the latter includes MTV Classic and Sundance TV. All the major networks are available except CBS. Anne Hidalgo, Mayor of Paris. Photos: Paul Rousteau 30-SECOND BIO: ANNE HIDALGO Title: Mayor of Paris Education: Master of social work; master of advanced studies, social and union law; Institute of Labor Studies, University of Lyon Nationality: French and Spanish. Hidalgo was born in San Fernando, Spain, and immigrated to Lyon, France, with her parents and older sister at age 2. “I am European,” she says. Political party: Socialist Here is the block quote and the lists Marz says there are five indicators that signal when it may be time for an organization to plan a retreat: Padgett grew up unafraid of scale, and scale has become his obsession. He was one of the prime movers of Disney’s $1 billion MagicBand and MyMagic+ project, which transformed how millions of people move through Walt Disney World—a massive experiment in friction-free user experience that has inspired projects in industries. Co.Design got a exclusive look at the process behind creating the Ocean Medallion, which promises to transform the cruise ship experience into a personalized voyage at massive scales: Where touchscreens will recognize you as you move past, a la Minority Report; where every drink you order and every activity you do will power new recommendations, refactored going, and know exactly how much help you might need; and where you can order anything you’d like, anywhere you’d like among the ship’s dozens of floors and rooms, and a waiter arrives with your order. Think of it like Uber for everything, powered by Netflix recommendations for meat space. Your excuse sounds like an old story. “If you’ve told yourself something along those lines before, and it feels like you’re not objectively looking at the situation,” David says. Your excuse is surrounded by emotions of anxiety, fear, or anger. Emotions are difficult and an excuse gives you relief, says David. It allows you to put aside a move to discomfort. It keeps you safe, but it doesn’t allow you to grow or move toward value. It allows you to put aside a move to discomfort. It keeps you safe, is surrounded by emotions of anxiety, fear, or anger. “Emotions are difficult and an excuse gives you relief.” By November 2017, when the first Medallion-class ship, the Regal Princess, sets sail, the best place to taste the future won’t be in a skunk works lab in Silicon Valley. It’ll be from a deckchair adrift in the Caribbean, with the smell of suntan lotion in the air and a mai tai in your hand. Whether it succeeds or not in its grandious goals, it’ll be a bellwether for design and technology, and a world where your environment is every bit as important as the device in your hand. When departments are functioning in silos and communication is breaking down. When you are bringing on new people and you want to incorporate them into the company’s culture. After a challenging time, such as cutbacks or a downturn in the market. During a merger that plans to combine two companies’ cultures. Annually for maintenance, but have a clear purpose and objectives about what you want to get out of it. Next, Marz advises finding the right setting for the culture of your organization, whether it’s a remote wilderness experience filled with outdoor activities or another setting to host team and leadership-building exercises to enjoy and remember. When preparing, Marz cautions leaders to make the distinction between a retreat and an offsite meeting. She recommends asking the following questions to determine whether you are planning a true retreat versus an offsite work or strategy session. Related link: Doppler Here One Earbuds: Bionic Hearing Is Tantalizing, But Not For Everybody DECIDING WHERE TO GO Biba Binotti, founder of U.K.-based leadership development consultancy Red Hat People, believes that getting people out of the office and on to a farm is a crucial element of staff development. “We do that because it busts reflect your congruence,” she says. In other words, the horse will respond positively when what being with horses reduces you feel words, the horse inside matches your outward expression. “The great thing is that, unlike humans, they are Nonjudgmental and don’t hold any grudges, they respond in the moment so you can also change your behavior and get instant feedback. Plus, just being with horses reduces stress and is calming.” Mollor giant water slides to casinos to musical shows to ice-skating extravaganzas. The largest cruise ship sailing today, the Harmony of the Seas, has 13 different restaurants—as many as the world’s largest resorts and casinos. Cruise ship heads like to say that cruising provides off-the-charts value. But then again, with so many options, so is the overload. Dan Whiteley is regents professor, McKnight presidential endowed chair in public health, and the founding director of the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. Mark Olshaker is an Emmy Award-winning documentary filmmaker and author. Excerpted from Deadliest Enemy, copyright © 2017 by Dr. Mike Osterholm and Mark Olshaker. Used with permission of Little, Brown and Company, New York. All rights reserved. Read More Inside Tim Cook’s Apple Playing The Long Game Inside Tim Cook’s Apple 9 Ways Tim Cook Has Transformed Apple Apple Music’s Bozoma Saint John: It’s Passion, Not Algorithms Related Video: Meet The Man Who Designed Trump’s Vodka Bottle Of “Envy And Status” if(typeof(jQuery)=="function"){(function($){$.fn.fitVids=function(){}})(jQuery)}; jwplayer('jwplayer_yK02riK6_G2hQKLvX_div').setup( {"playlist":"https:\/\/content.jwplatform.com\/feeds\/yK02riK6.json","ph":2} );


News Article | May 5, 2017
Site: www.businesswire.com

CHANDLER, Ariz.--(BUSINESS WIRE)--At 11:01 p.m. on Thursday, May 4, 2017, the Arizona Senate passed HB 2547: university infrastructure capital financing; appropriations, paving the way for up to $1 billion in bonds to expand and maintain university research infrastructure at Arizona’s public universities. HB2547 is part of a set of budget bills that make up Arizona’s $9.8 billion budget for the fiscal year the begins on July 1, 2017. The bill’s primary sponsor was Representative Paul Boyer (LD-20). Representative Boyer is the Chairman of the House Education Committee, and is a member of the House Health and County and Municipal Affairs Committees. A vehicle supporting the $1 billion investment in Arizona’s University Research Infrastructure was originally proposed in Arizona Governor Doug Ducey’s Executive Budget on January 13, 2017. The Governor’s Plan proposed allowing Arizona’s three state universities to apply the Transaction Privilege Tax (TPT) revenue that they create to support up to $1 billion in bonding for research and development, and deferred maintenance construction projects. While support for investing in Arizona’s future by expanding our university research infrastructure was strong in the community and with members of the legislature, concerns over the use of TPT revenue and the impact that it could have on other stakeholders was a legislative concern. Achieving the goal of an $1 billion investment would require creativity, collaboration and compromise. Reaching the Destination with a Different Vehicle Following months of committee hearings, discussions, stakeholder meetings and communication with constituents, a new funding plan was developed that combines a percentage of the new licensure and royalty agreements that are the result of research at Arizona’s public universities, with state funding support and a university match to allow for up to $1 billion in bonding capacity for Arizona’s public universities. This plan became HB2547, which first passed in the Arizona House of Representatives (33-26), followed by the Arizona Senate (23-7), paves the way for a $1 billion investment in Arizona’s public universities and is on the way to the Governor’s desk. To view the full summary of HB 2547, visit http://www.azleg.gov/legtext/53leg/1R/summary/H.HB2547_05-04-17_HOUSEENGROSSED.DOCX.htm. In 2003, the Arizona Legislature authorized an annual appropriation of $35 million to construct roughly $500 million worth of university research facilities that was championed by then-Speaker Pro Tempore Bob Robson. These projects included the Biodesign Institute at Arizona State University, The University of Arizona’s Keating Bioresearch Building, which houses the UA BIO5 Institute, and Arizona Biomedical Collaborative 1 on the Phoenix Biomedical Campus. At Northern Arizona University, the Applied Research and Development facility has enabled the university to expand its research in the areas of national defense and infectious disease. Since the state’s investment in 2003, research activity conducted at Arizona’s public universities has increased 77 percent and now totals nearly $1.1 billion each year. University invention disclosures have increased 154 percent. Degrees awarded in high-demand fields, including key STEM (Science, Technology, Engineering and Math) fields, have increased 40 percent in the past six years alone. In fiscal 2015, Arizona’s three public universities were responsible for an estimated 102,000 jobs and $11 billion in total economic impact. “Our investments in university research infrastructure have been and will be a major economic driver,” shared Joan Koerber-Walker, president & CEO of the Arizona Bioindustry Association (AZBio). “Yet, measuring this impact in a purely economic sense overlooks the greater value that life science research represents. The greatest value comes from the life-saving and life-changing innovations that will make life better for people in Arizona and around the world. Arizona university researchers and their industry partners are discovering, developing, and delivering products and services that will help people stay healthy, aid them when they are ill and improve their quality of life. By doubling down on our earlier research infrastructure investments, Arizona’s leaders are paving the way to a brighter future for the people of Arizona. We are truly grateful to Governor Doug Ducey and the Arizona Legislature for their vision and their commitment to invest in Arizona’s future.” “Arizona has passed a budget that prioritizes education, boosts teacher pay and invests in our universities — all without raising taxes on hardworking Arizonans,” said Governor Ducey. “For the first time in a decade, we are making significant and lasting investments to grow our state — in state parks, in public schools and universities, in our roads and highways, and in programs to combat drug addiction, provide second chances to inmates and place foster children in permanent homes. This would not be possible without the hard work to balance our budget over recent years. And it should come as no surprise that we are investing where it can really make a difference. I thank the legislature for their hard work and look forward to building on these gains to continue expanding opportunity for all Arizonans.” About the Arizona Bioindustry Association, Inc. (AZBio) A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.

Loading BIO Co. collaborators
Loading BIO Co. collaborators